1. Home
  2. KMT vs BEAM Comparison

KMT vs BEAM Comparison

Compare KMT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kennametal Inc.

KMT

Kennametal Inc.

HOLD

Current Price

$29.31

Market Cap

2.1B

Sector

Industrials

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.05

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMT
BEAM
Founded
1938
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.3B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
KMT
BEAM
Price
$29.31
$27.05
Analyst Decision
Hold
Strong Buy
Analyst Count
6
12
Target Price
$25.83
$48.09
AVG Volume (30 Days)
809.0K
2.0M
Earning Date
02-04-2026
11-04-2025
Dividend Yield
2.73%
N/A
EPS Growth
N/A
N/A
EPS
1.22
N/A
Revenue
$1,982,871,000.00
$55,701,000.00
Revenue This Year
$7.69
N/A
Revenue Next Year
$3.82
$26.52
P/E Ratio
$24.03
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.30
$13.53
52 Week High
$29.89
$35.25

Technical Indicators

Market Signals
Indicator
KMT
BEAM
Relative Strength Index (RSI) 70.22 57.59
Support Level $27.47 $26.83
Resistance Level $29.89 $28.28
Average True Range (ATR) 0.58 1.60
MACD 0.04 0.27
Stochastic Oscillator 74.45 63.54

Price Performance

Historical Comparison
KMT
BEAM

About KMT Kennametal Inc.

Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: